Elawad 1991.
Methods | Design: Randomised controlled trial. Setting: Malmo General Hospital, Sweden. | |
Participants | N = 60 patients undergoing elective primary total hip replacement.
[*data for these groups were combined for the review's analysis to create one PAD group] |
|
Interventions |
Timing of autologous blood collection/retransfusion: Donated 31 to 40 days before operation, with nine to 16 days between each phlebotomy. Volume of autologous blood collected/retransfused: Each donated on average between 2.8 and 3.0 units. Iron supplementation: Two of the four groups were exposed to iron supplementation. One of these received iron supplementation as ferrous sulfate 100 mg three times daily, starting after the first phlebotomy, and the other received the iron supplementation plus folate supplementation as folate 5 mg three times daily, starting after the first phlebotomy. Use of transfusion threshold: Not mentioned. |
|
Outcomes | Outcomes reported: Number of patients exposed to allogeneic blood (n), allogeneic blood transfused (units), blood loss (mL), deep vein thrombosis (n), pulmonary embolus (n), biochemical parameters. | |
Notes | Period of study: January 1988 to February 1989 Length of study: Not reported. A priori sample size: Not reported. Baseline comparability: Age and gender of the patients were similar in all groups. Operation time (mean ± SD) was longer in the no‐PAD control group (125 ± 18) than the PAD groups (116 ± 19; 116 ± 26; 109 ± 20). | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Adequate sequence generation? | Unclear risk | No information. |
Allocation concealment? | Unclear risk | Patients were allocated by means of sealed envelopes |
Blinding? All outcomes | Unclear risk | No information. |
Intention‐to‐treat analysis? | Unclear risk | No information. |